FAGR Stock Analysis: Fagron | BR
Drug Manufacturers - Specialty & Generic | BR, Belgium | Market Cap: 1.655m EUR | 12M Return: 7.7% | BE0003874915 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.20M
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Fagron NV (FAGR) is a Belgian pharmaceutical compounding company that delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates through three segments: Essentials, Brands, and Compounding Services, offering a diverse portfolio of proprietary and compounded products including DiluCap, DiluTab, Imuno TF Complex, Pigmerise, Pentravan, Nourisil MD, Neogen, TrichoConcept, Fagron Advanced Derma, SyrSpend SF, and Cleoderm. The company also supports prescribers, hospitals, and pharmacists through the Fagron Academy, providing education and professional development. Originally founded in 1990 as Arseus NV, it rebranded to Fagron NV in January 2015 and is headquartered in Nazareth, Belgium.
Pharmaceutical compounding is a specialized segment of the broader pharmaceutical industry focused on preparing customized medications tailored to individual patient needs, such as specific dosages, formulations, or combinations not commercially available. This sector serves niche therapeutic areas including dermatology, hormone replacement, pediatrics, and rare disease treatments, and often operates at the intersection of pharmacy practice and specialty manufacturing.
- Compounding Services and Essentials segments post strong revenue growth
- Tightening FDA compounding regulations pressure operating margins
- Hair care Neogen and dermatology brands expand high-margin mix
| Net Income: 91.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.12 > 1.0 |
| NWC/Revenue: 21.02% < 20% (prev 17.55%; Δ 3.47% < -1%) |
| CFO/TA 0.09 > 3% & CFO 136.8m > Net Income 91.7m |
| Net Debt (569.3m) to EBITDA (200.8m): 2.83 < 3 |
| Current Ratio: 1.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (73.5m) vs 12m ago 0.66% < -2% |
| Gross Margin: 37.31% > 18% (prev 45.75%; Δ -8.44% > 0.5%) |
| Asset Turnover: 77.79% > 50% (prev 82.09%; Δ -4.30% > 0%) |
| Interest Coverage Ratio: 4.40 > 6 (EBIT TTM 150.2m / Interest Expense TTM 34.2m) |
| A: 0.14 (Total Current Assets 496.5m - Total Current Liabilities 280.3m) / Total Assets 1.53b |
| B: 0.23 (Retained Earnings 347.7m / Total Assets 1.53b) |
| C: 0.11 (EBIT TTM 150.2m / Avg Total Assets 1.32b) |
| D: 0.64 (Book Value of Equity 594.7m / Total Liabilities 925.7m) |
| Altman-Z'' = 3.11 = A |
| DSRI: 1.14 (Receivables 122.6m/96.0m, Revenue 1.03b/918.8m) |
| GMI: 1.23 (GM 45.75% / 37.31%) |
| AQI: 1.05 (AQ_t 0.53 / AQ_t-1 0.51) |
| SGI: 1.12 (Revenue 1.03b / 918.8m) |
| TATA: -0.03 (NI 91.7m - CFO 136.8m) / TA 1.53b) |
| Beneish M = -2.59 (Cap -4..+1) = A |
As of October 14, 2026, the stock is trading at EUR 22.20 with a total of 151,255 shares traded. Over the past week, the price has changed by -3.69%, over one month by +4.96%, over three months by -7.50% and over the past year by +7.74%.
Current recommended Stop Loss: 21.30 (which is 4.1% or 1.6 ATR below the current price).
Fagron has no consensus analysts rating.
P/E Trailing = 18.04
P/E Forward = 13.7741
P/S = 1.6091
P/B = 2.6843
P/EG = 15.8442
Revenue TTM = 1.03b EUR
EBIT TTM = 150.2m EUR
EBITDA TTM = 200.8m EUR
Long Term Debt = 568.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 18.2m EUR (from shortTermDebt, last quarter)
Debt = 700.4m EUR (from shortLongTermDebtTotal, last quarter) + Leases 63.9m
Net Debt = 569.3m EUR (calculated: Debt 700.4m - CCE 131.1m)
Enterprise Value = 2.22b EUR (1.65b + Debt 700.4m - CCE 131.1m)
Interest Coverage Ratio = 4.40 (Ebit TTM 150.2m / Interest Expense TTM 34.2m)
EV/FCF = 18.75x (Enterprise Value 2.22b / FCF TTM 118.6m)
FCF Yield = 5.33% (FCF TTM 118.6m / Enterprise Value 2.22b)
FCF Margin = 11.53% (FCF TTM 118.6m / Revenue TTM 1.03b)
Net Margin = 8.92% (Net Income TTM 91.7m / Revenue TTM 1.03b)
Gross Margin = 37.31% ((Revenue TTM 1.03b - Cost of Revenue TTM 644.8m) / Revenue TTM)
Gross Margin QoQ = 20.12% (prev 57.26%)
Tobins Q-Ratio = 1.46 (Enterprise Value 2.22b / Total Assets 1.53b)
Interest Expense / Debt = 4.88% (Interest Expense 34.2m / Debt 700.4m)
Taxrate = 20.82% (24.3m / 116.5m)
NOPAT = 118.9m (EBIT 150.2m * (1 - 20.82%))
Current Ratio = 1.77 (Total Current Assets 496.5m / Total Current Liabilities 280.3m)
Debt / Equity = 1.18 (Debt 700.4m / totalStockholderEquity, last quarter 594.7m)
Debt / EBITDA = 2.83 (Net Debt 569.3m / EBITDA 200.8m)
Debt / FCF = 4.80 (Net Debt 569.3m / FCF TTM 118.6m)
Total Stockholder Equity = 537.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.94% (Net Income 91.7m / Total Assets 1.53b)
RoE = 17.08% (Net Income TTM 91.7m / Total Stockholder Equity 537.2m)
RoCE = 13.59% (EBIT 150.2m / Capital Employed (Equity 537.2m + L.T.Debt 568.0m))
RoIC = 9.82% (NOPAT 118.9m / Invested Capital 1.21b)
WACC = 5.51% (E(1.65b)/V(2.36b) * Re(6.21%) + D(700.4m)/V(2.36b) * Rd(4.88%) * (1-Tc(0.21)))
Discount Rate = 6.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.00 | Cagr: 0.37%
[DCF] Terminal Value 77.97% ; FCFF base≈111.0m ; Y1≈127.3m ; Y5≈187.3m
[DCF] Fair Price = 30.65 (EV 2.82b - Net Debt 569.3m = Equity 2.25b / Shares 73.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.53 | Revenue CAGR: 12.05% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.43 | Chg30d=-1.79% | Revisions=-40% | GrowthEPS=+14.6% | GrowthRev=+19.9%
EPS next Year (2027-12-31): EPS=1.64 | Chg30d=-0.12% | Revisions=+0% | GrowthEPS=+15.0% | GrowthRev=+8.8%
[Analyst] Revisions Ratio: -29% (up=1, down=3)